Globus Medical, Inc. (GMED)

While the top- and bottom-line numbers for Globus Medical (GMED) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Globus Medical (GMED) came out with quarterly earnings of $1.28 per share, beating the Zacks Consensus Estimate of $1.06 per share. This compares to earnings of $0.84 per share a year ago.

Globus Medical, Inc. (GMED) Q4 2025 Earnings Call Transcript

AUDUBON, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology solutions company, today announced its financial results for the fourth quarter and year ended December 31, 2025.

Datadog gets hit on AI disruption fears, Whirlpool pushes $800 million stock offering, and more

Investors looking for stocks in the Medical - Instruments sector might want to consider either Globus Medical (GMED) or Masimo (MASI). But which of these two stocks is more attractive to value investors?

Globus Medical, Inc. (NYSE: GMED - Get Free Report) EVP Kelly Huller sold 10,000 shares of the company's stock in a transaction that occurred on Thursday, February 12th. The shares were sold at an average price of $87.67, for a total value of $876,700.00. The sale was disclosed in a document filed with the Securities and

Beyond analysts' top-and-bottom-line estimates for Globus Medical (GMED), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2025.

Rhumbline Advisers decreased its stake in shares of Globus Medical, Inc. (NYSE: GMED) by 3.2% during the undefined quarter, according to the company in its most recent filing with the SEC. The firm owned 281,944 shares of the medical device company's stock after selling 9,227 shares during the quarter. Rhumbline Advisers owned 0.21%

AUDUBON, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the fourth quarter and full-year ended December 31, 2025 after the market close on Tuesday, February 24, 2026.

Globus Medical (GMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Bessemer Group Inc. boosted its holdings in shares of Globus Medical, Inc. (NYSE: GMED) by 26.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 30,357 shares of the medical device company's stock after buying an additional 6,400

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

The AI sector remains highly attractive, with top quant-rated stocks offering superior growth and fundamentals despite recent volatility and sharp pullbacks. Head of Quantitative Strategy at Seeking Alpha, Steven Cress, shares which AI stocks look best for this year.

Investors looking for stocks in the Medical - Instruments sector might want to consider either Globus Medical (GMED) or Penumbra (PEN). But which of these two stocks is more attractive to value investors?